Clinical trial
A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors
NCT02588170 is registered in ClinicalTrials.gov with Hutchison Medipharma Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors
- Lead sponsor
- Hutchison Medipharma Limited
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 7, 2015
- Completion date
- July 7, 2022
- Enrollment
- 219 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.